At the heart of this research lies the nuclear factor-kappa B (NF-κB) inhibitor alpha (IκBα), classically known for its cytoplasmic function in sequestering NF-κB and preventing its transcriptional activity. Alessio and colleagues reveal an unexpected mitochondrial localization of IκBα within cancer cells, where it assumes a radically different role by orchestrating metabolic rewiring that favors tumor growth and survival. This mitochondrial pool of IκBα appears to act as a pivotal regulator of mitochondrial bioenergetics and redox homeostasis, thereby enabling cancer cells to adapt dynamically to metabolic stress and enhance their proliferative capacity.

The authors employed a comprehensive suite of molecular biology techniques, metabolomics, and in vivo cancer models to dissect how mitochondrial IκBα modulates cancer metabolism. Their data demonstrate that mitochondrial IκBα enhances oxidative phosphorylation (OXPHOS) efficiency and stabilizes mitochondrial complex I assembly, resulting in increased ATP production and reduced reactive oxygen species (ROS) leakage. This bioenergetic optimization allows cancer cells to meet elevated energetic demands while mitigating oxidative damage, effectively fostering a more robust and resilient tumor phenotype.

Beyond metabolic control, Alessio et al. report that mitochondrial IκBα profoundly influences the tumor microenvironment, particularly by activating the endothelium. This activation promotes vascular remodeling and permeability, facilitating tumor angiogenesis and nutrient supply. Intriguingly, the study highlights that mitochondrial IκBα drives upregulation of endothelial adhesion molecules and pro-inflammatory cytokines, which collectively potentiate endothelial cell activation and recruitment of immune and stromal cells that support tumor progression.

A particularly novel finding of this study is the link between mitochondrial IκBα and cancer-associated thrombosis, a major cause of morbidity and mortality in cancer patients. The researchers show that mitochondrial IκBα enhances the pro-thrombotic phenotype of tumor endothelial cells by inducing expression of tissue factor and other coagulation modulators. This creates a microenvironment conducive to platelet aggregation and fibrin deposition, promoting thrombus formation that not only facilitates metastatic dissemination but also exacerbates cancer-associated coagulopathies.

The implications of these findings extend to clinical oncology, where targeting mitochondrial IκBα could represent a therapeutic avenue to disrupt metabolic plasticity, inhibit pathological endothelial activation, and reduce thrombosis in cancer patients. Alessio and colleagues suggest that therapies aimed at modulating mitochondrial IκBα function may confer dual benefits: direct suppression of tumor cell bioenergetics and mitigation of the pro-metastatic vascular niche.

Importantly, the study sheds light on the molecular underpinnings of metabolic heterogeneity within tumors. By delineating how mitochondrial IκBα selectively enhances OXPHOS, the authors challenge the traditional Warburg-centric model of cancer metabolism and underscore the nuanced metabolic adaptations cancer cells exploit to survive in hostile microenvironments.

The mechanistic insights provided by this work also highlight the intricate integration of mitochondrial signaling pathways with inflammatory and coagulation networks in cancer. Mitochondrial IκBα emerges as a central node that links metabolic control to immune modulation and vascular pathology, emphasizing the multifaceted nature of tumor progression.

Technically, the research leveraged CRISPR-Cas9 mediated gene editing to ablate mitochondrial IκBα specifically, enabling the dissection of its functions without perturbing cytoplasmic NF-κB inhibition. This precise approach allowed delineation of the unique contributions of mitochondrial IκBα, enhancing the specificity and relevance of the study.

Furthermore, metabolomic profiling unveiled that mitochondrial IκBα deficiency causes accumulation of tricarboxylic acid (TCA) cycle intermediates and a compensatory increase in glycolytic flux, highlighting adaptive metabolic shifts cancer cells undergo when deprived of mitochondrial IκBα’s regulatory influence.

The endothelial phenotypes observed were corroborated by in vivo models demonstrating reduced tumor angiogenesis and thrombus formation upon mitochondrial IκBα inhibition, suggesting that the mitochondrial regulator exerts systemic effects beyond cancer cells themselves.

This pioneering investigation opens numerous avenues for future research, including exploration of mitochondrial IκBα’s role across different cancer types and its potential interplay with other mitochondrial regulatory proteins. Moreover, understanding how mitochondrial IκBα expression is controlled at the transcriptional and post-translational levels may reveal additional therapeutic targets.

Overall, Alessio et al.’s work shifts paradigms by portraying mitochondrial IκBα not merely as a classical NF-κB inhibitor but a multifaceted mitochondrial orchestrator of cancer progression, integrating metabolic, vascular, and thrombotic dimensions into a coherent oncogenic program.

As cancer therapy increasingly embraces metabolic and microenvironmental targets, mitochondrial IκBα stands out as a promising biomolecular fulcrum to exploit, potentially transforming approaches to managing cancer progression and metastasis in the clinic.

Subject of Research:
Mitochondrial IκBα role in cancer progression through metabolic remodeling, endothelial activation, and thrombotic spread.

Article Title:
Mitochondrial IκBα fuels cancer progression through metabolic rewiring, endothelial activation, and thrombotic spread.

Article References:
Alessio, M., Petiti, J., Basile, R. et al. Cell Death Discov. (2026). https://doi.org/10.1038/s41420-026-03022-0

Image Credits: AI Generated

DOI:
https://doi.org/10.1038/s41420-026-03022-0

Keywords:
Mitochondrial IκBα, cancer metabolism, oxidative phosphorylation, endothelial activation, tumor microenvironment, cancer-associated thrombosis, metabolic rewiring, vascular remodeling, tissue factor, pro-thrombotic phenotype.

Human prostate cancer samples exhibiting perineural invasion—a condition where cancer cells encroach upon or surround nerves—displayed a significantly elevated mitochondrial load within cancer cells proximal to nerves. Using high-throughput multispectral imaging coupled with machine learning algorithms, researchers quantified mitochondrial abundance across tens of thousands of cells. Their precise spatial analysis revealed that cancer cells neighboring nerves harbored considerably more mitochondria than their distant counterparts, suggesting a nerve-dependent metabolic advantage in these cancer cells.

To further dissect whether this phenomenon involved actual mitochondrial transfer rather than mere mitochondrial biogenesis within cancer cells, the research team leveraged a clinical trial involving chemical denervation of the human prostate using botulinum neurotoxin A (BoNT/A). This intervention selectively reduced neuronal activity at the tumor site, serving as a natural experiment to observe the influence of neuronal innervation on cancer mitochondrial content. Remarkably, cancer cells on the denervated side exhibited a stark reduction in mitochondrial load, directly linking neuronal presence to mitochondrial enrichment in tumor cells and strongly implying transfer of mitochondria from nerves to cancer.

To substantiate these findings with robust in vivo models, the researchers employed a BALB/c mouse xenograft system, where murine dorsal root ganglion (DRG) neurons innervating the mammary fat pad were genetically modified to express a mitochondria-targeted green fluorescent protein (GFP) reporter under the synapsin-1 promoter, allowing for neuron-specific mitochondrial labeling. Following the injection of 4T1 breast cancer cells tagged with a red fluorescent protein (mCherry) into the same fat pad, analysis of emerging tumors by flow cytometry detected a distinct subpopulation of cancer cells emitting the GFP mitochondrial signal. This provided compelling evidence that mouse host neurons transferred mitochondria directly into malignant cells within the tumor microenvironment.

Notably, this transfer was shown to be specific to mitochondria, as a control lentiviral construct encoding a nucleus-localized GFP failed to show any signal exchange, ruling out nonspecific protein transfer or artifact. This elegant genetic design confirmed that intact mitochondria, rather than soluble proteins or other organelles, crossed from host neurons into cancer cells in situ, emphasizing the precision and selectivity of this intercellular communication.

Beyond imaging and fluorescence-based assays, the team implemented advanced genetic approaches to detect mitochondrial DNA (mtDNA) transfer at the molecular level. By identifying distinct mtDNA polymorphisms inherent to the host mouse strain and the transplanted cancer cells through Sanger sequencing, they established a unique molecular signature. Cancer cells recovered from tumors via fluorescence-activated cell sorting (FACS) underwent deep Oxford Nanopore sequencing to detect the presence of host-derived mtDNA within the tumor cell population. The results definitively demonstrated heteroplasmy—cancer cells contained a mixture of their own and neuron-derived mtDNA—validating that mitochondrial transfer is not merely a superficial event but involves functional genetic material.

Importantly, denervation via BoNT/A treatment in the xenograft model resulted in a significant decrease of approximately 35% in the mitochondrial transfer events from neurons to cancer cells. This implies that neural activity and integrity are key drivers of mitochondrial donation, and that interfering with nerve presence or function may modulate tumor metabolism and progression by denying cancer cells this mitochondrial influx.

The implications of nerve-to-cancer mitochondrial transfer are profound, as mitochondria are central to energy production, metabolic adaptation, and apoptotic regulation. Mitochondrial acquisition by cancer cells could endow them with enhanced bioenergetic capacity, resistance to metabolic stress, and even influence metastatic potential. This discovery adds a new dimension to tumor–nerve interactions, previously focused largely on growth factor secretion and neurotransmitter release, by highlighting organelle-level communication.

From a therapeutic standpoint, these findings suggest new intervention points. Chemical denervation or strategies to block mitochondrial transfer mechanisms may disrupt this symbiotic relationship, potentially depriving cancer cells of vital metabolic support and hindering tumor growth and metastasis. Furthermore, the use of neuron-specific mitochondrial reporters in preclinical models paves the way for real-time imaging and therapeutic monitoring in future studies.

The researchers’ methodical approach, combining clinical patient sample analysis, advanced imaging platforms, genetic manipulation, and rigorous sequencing, exemplifies the power of multidisciplinary strategies in unraveling complex cellular communications. Their use of machine learning for image quantification allowed unprecedented cellular resolution and statistical power to detect subtle spatial mitochondrial variations linked to nervous system presence.

As cancer research continues to unravel the tumor microenvironment’s multifaceted influencers, the role of nerves emerges as a critical, active participant rather than a mere passive structure. The revelation that neurons can donate mitochondria to cancer cells during metastasis challenges classical tumor biology and invites new perspectives on tumor–neuron crosstalk.

Future research will need to clarify the precise molecular machinery mediating mitochondrial transfer, such as tunneling nanotubes, extracellular vesicles, or synaptic-like junctions, and how these processes are regulated by the tumor microenvironment. Understanding the downstream metabolic and signaling consequences of mitochondrial acquisition on cancer cell behavior will be equally critical.

In sum, this pioneering study illuminates a novel biological axis in cancer metastasis—the nerve-to-cancer mitochondrial conduit—adding an organelle-centric lens to investigate tumor progression and offering novel targets for therapeutic innovation. As interdisciplinary efforts converge, exploiting neural physiology to impede cancer’s metabolic support systems may forge new frontiers in oncology.

Subject of Research: Mitochondrial transfer from nerves to cancer cells during cancer metastasis

Article Title: Nerve-to-cancer transfer of mitochondria during cancer metastasis

Article References:
Hoover, G., Gilbert, S., Curley, O. et al. Nerve-to-cancer transfer of mitochondria during cancer metastasis. Nature (2025). https://doi.org/10.1038/s41586-025-09176-8